西那卡塞治疗继发性甲状旁腺功能亢进症的研究进展
发布时间：2019-01-19 16:37
【摘要】：目的:了解西那卡塞治疗继发性甲状旁腺功能亢进症(SHPT)的临床研究进展。方法:查阅近年来国内外相关文献,就西那卡塞对血管钙化的影响、致心血管事件和死亡事件的研究进行归纳和总结,并对西那卡塞潜在的生存获益机制进行分析。结果:西那卡塞可降低SHPT患者甲状旁腺激素水平,提高其对矿物质和骨代谢的控制力。尽管初期的研究结果尚无定论,但以ADVANCE和EVOLVE为代表的多项随机对照试验结果均提示西那卡塞对延缓心血管钙化进程、降低心血管事件发生率、降低死亡率和降低骨折风险等方面均有潜在作用。这些阳性的研究成果与西那卡塞对骨代谢和血管钙化的有益效应数据具有一致性,为西那卡塞的潜在生存获益作用提供了支持。结论:现有研究结果仍缺乏决定性的证据,仍需进一步验证西那卡塞对慢性肾脏病所致SHPT患者临床结局的有利作用。
[Abstract]:Objective: to investigate the clinical progress in the treatment of (SHPT) with secondary hyperparathyroidism. Methods: the effects of Sinakaser on vascular calcification, cardiovascular events and death events were summarized, and the mechanism of Sinacase's potential survival and benefit was analyzed. Results: cilazepine could decrease the level of parathyroid hormone and improve the control of mineral and bone metabolism in SHPT patients. Although the results of the initial study are not conclusive, the results of several randomized controlled trials, represented by ADVANCE and EVOLVE, suggest that Sinakaser can delay the process of cardiovascular calcification and reduce the incidence of cardiovascular events. Reducing mortality and reducing fracture risk have potential effects. These positive results are consistent with the data on the beneficial effects of Sinakaser on bone metabolism and vascular calcification, and support the potential survival benefits of Sinakaser. Conclusion: there is still no conclusive evidence in the present study, and it is necessary to further verify the beneficial effect of Sinakasai on the clinical outcome of patients with SHPT caused by chronic kidney disease.
【作者单位】： 呼伦贝尔市人民医院临床药学部;内蒙古民族大学呼伦贝尔医学院;呼伦贝尔市中蒙医院药剂科;
【分类号】：R582.1
本文编号：2411542
[Abstract]:Objective: to investigate the clinical progress in the treatment of (SHPT) with secondary hyperparathyroidism. Methods: the effects of Sinakaser on vascular calcification, cardiovascular events and death events were summarized, and the mechanism of Sinacase's potential survival and benefit was analyzed. Results: cilazepine could decrease the level of parathyroid hormone and improve the control of mineral and bone metabolism in SHPT patients. Although the results of the initial study are not conclusive, the results of several randomized controlled trials, represented by ADVANCE and EVOLVE, suggest that Sinakaser can delay the process of cardiovascular calcification and reduce the incidence of cardiovascular events. Reducing mortality and reducing fracture risk have potential effects. These positive results are consistent with the data on the beneficial effects of Sinakaser on bone metabolism and vascular calcification, and support the potential survival benefits of Sinakaser. Conclusion: there is still no conclusive evidence in the present study, and it is necessary to further verify the beneficial effect of Sinakasai on the clinical outcome of patients with SHPT caused by chronic kidney disease.
【作者单位】： 呼伦贝尔市人民医院临床药学部;内蒙古民族大学呼伦贝尔医学院;呼伦贝尔市中蒙医院药剂科;
【分类号】：R582.1
【相似文献】
中国硕士学位论文全文数据库 前1条
1 尹鹤立;西那卡塞对继发性甲状旁腺功能亢进症透析患者疗效及死亡率影响的Meta分析[D];广西医科大学;2017年
，本文编号：2411542
本文链接：https://www.wllwen.com/yixuelunwen/nfm/2411542.html
最近更新
教材专著
